InsiderTrades.com logo
First JFK… next Elon?
From Porter & Company   |   Ad
Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.
I share with you in this special investigative documentary.

IOBT Insider Trading

Insider Ownership Percentage: 2.30%
Insider Buying (Last 12 Months): $18,632.50
Insider Selling (Last 12 Months): $1,860,484.74

IO Biotech Insider Trading History Chart

This chart shows the insider buying and selling history at IO Biotech by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

IO Biotech Share Price & Price History

Current Price: $0.90
Price Change: ▲ Price Increase of +0.0104 (1.17%)
As of 12/24/2024 01:19 PM ET

This chart shows the closing price history over time for IOBT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Pocket $1,100 in 60 Seconds per Day with AI?
From Prosper Trading Academy   |   Ad

What if I told you 60 seconds a day could completely change your life?

My AI-powered trading system finds high-probability option trades in less than 60 seconds a day

Click HERE to access this powerful AI Trading System

IO Biotech Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/23/2024Amy SullivanCFOBuy10,250$0.83$8,507.5084,632View SEC Filing Icon  
12/23/2024Mai-Britt ZoccaCEOBuy12,500$0.81$10,125.0049,891View SEC Filing Icon  
7/25/2024Holdings A/S NovoMajor ShareholderSell51,522$1.33$68,524.264,377,927View SEC Filing Icon  
5/10/2024Holdings A/S NovoMajor ShareholderSell658,809$1.22$803,746.984,429,449View SEC Filing Icon  
2/9/2024Holdings A/S NovoMajor ShareholderSell658,809$1.50$988,213.505,088,258View SEC Filing Icon  
11/21/2023Brian BurkavageCAOBuy5,000$0.99$4,950.006,500View SEC Filing Icon  
8/9/2023Vivo Capital Ix, LlcMajor ShareholderBuy3,157,894$1.90$5,999,998.603,157,894View SEC Filing Icon  
3/17/2023Amy SullivanCFOBuy25,000$2.32$58,000.0025,000View SEC Filing Icon  
See Full Table
Grab This Altcoin Before Trump's Crypto Announcement
From Crypto 101 Media   |   Ad
Grab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which is why I'm recommending ONE coin to all investors right now.
Click here to check it out now

SEC Filings (Institutional Ownership Changes) for IO Biotech (NASDAQ:IOBT)

54.76% of IO Biotech stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at IOBT by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

IO Biotech Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
10/24/2024Novo Holdings A S3,354,449$3.52M0.2%-24.3%5.092%Search for SEC Filing on Google Icon
8/20/2024Novo Holdings A S4,429,449$5.18M0.3%-12.9%6.723%Search for SEC Filing on Google Icon
8/15/2024Armistice Capital LLC1,545,000$1.81M0.0%-10.4%2.345%Search for SEC Filing on Google Icon
8/12/2024XTX Topco Ltd26,555$31K0.0%+67.4%0.040%Search for SEC Filing on Google Icon
8/9/2024Renaissance Technologies LLC180,800$0.21M0.0%+8.1%0.274%Search for SEC Filing on Google Icon
2/15/2024PFM Health Sciences LP2,341,107$4.40M0.3%+73.0%3.554%Search for SEC Filing on Google Icon
2/13/2024Stonepine Capital Management LLC1,666,037$3.13M1.4%-15.7%2.529%Search for SEC Filing on Google Icon
2/13/2024Armistice Capital LLC1,924,000$3.62M0.0%-10.4%2.920%Search for SEC Filing on Google Icon
11/15/2023Armistice Capital LLC2,148,000$3.03M0.0%N/A3.260%Search for SEC Filing on Google Icon
11/14/2023Stonepine Capital Management LLC1,975,308$2.79M0.9%N/A2.998%Search for SEC Filing on Google Icon
11/14/2023Pivotal bioVenture Partners Investment Advisor LLC864,197$1.22M0.5%N/A1.312%Search for SEC Filing on Google Icon
11/8/2023Vivo Capital LLC6,173,439$8.71M1.1%+104.7%9.371%Search for SEC Filing on Google Icon
7/25/2023Summit Trail Advisors LLC43,744$86K0.0%N/A0.152%Search for SEC Filing on Google Icon
2/14/2023RA Capital Management L.P.1,127,260$2.59M0.1%-39.3%3.911%Search for SEC Filing on Google Icon
11/14/2022Psagot Value Holdings Ltd. Israel40,846$0.11M0.0%N/A0.142%Search for SEC Filing on Google Icon
11/2/2022Victory Capital Management Inc.43,741$0.12M0.0%N/A0.152%Search for SEC Filing on Google Icon
2/15/2022Samsara BioCapital LLC1,120,437$7.17M1.4%N/A3.888%Search for SEC Filing on Google Icon
2/15/2022Capital World Investors1,235,000$8.11M0.0%N/A4.286%Search for SEC Filing on Google Icon
2/14/2022Soleus Capital Management L.P.672,734$4.31M0.4%N/A2.335%Search for SEC Filing on Google Icon
2/14/2022Novo Holdings A S3,277,932$20.98M1.0%N/A11.376%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
IO Biotech logo
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
Read More on IO Biotech

Today's Range

Now: $0.90
Low: $0.86
High: $0.91

50 Day Range

MA: $0.98
Low: $0.68
High: $1.33

52 Week Range

Now: $0.90
Low: $0.66
High: $2.10

Volume

219,251 shs

Average Volume

263,221 shs

Market Capitalization

$59.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.27

Who are the company insiders with the largest holdings of IO Biotech?

IO Biotech's top insider investors include:
  1. Holdings A/S Novo (Major Shareholder)
  2. Vivo Capital Ix, Llc (Major Shareholder)
  3. Amy Sullivan (CFO)
  4. Mai-Britt Zocca (CEO)
  5. Brian Burkavage (CAO)
Learn More about top insider investors at IO Biotech.

Who are the major institutional investors of IO Biotech?

IO Biotech's top institutional investors include:
  1. Novo Holdings A S — 5.09%
Learn More about top institutional investors of IO Biotech stock.

Which institutional investors are selling IO Biotech stock?

Within the last quarter, IOBT stock was sold by these institutional investors:
  1. Novo Holdings A S
First JFK… next Elon?
From Porter & Company   |   Ad
Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.
I share with you in this special investigative documentary.